Avisa Pharma
Avisa Pharma is a privately held Santa Fe, New Mexico-based diagnostics company developing a test to differentiate virulent Streptococcus pneumoniae bacterial lung infections from viral lung infections, founded in 2010 and operating with 1-10 employees.
- Company typePrivate
- Founded2010
- HeadquartersSanta Fe, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Avisa Pharma firmographics
Firmographics- Name
- Avisa Pharma
- Website
- https://avisadx.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Avisa Pharma is a privately held Santa Fe, New Mexico-based diagnostics company developing a test to differentiate virulent Streptococcus pneumoniae bacterial lung infections from viral lung infections, founded in 2010 and operating with 1-10 employees.
- Ownership category
- akta.pro rank
Avisa Pharma industry classification
Industry- Product category
- Infectious Disease Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industries
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)
Keywords
Where Avisa Pharma is headquartered
LocationHeadquarters
- HQ city
- Santa Fe
- HQ country
- United States
- HQ region
- North America
Markets served
Avisa Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Avisa Pharma product offering
Product offeringCore offering
Avisa Pharma provides a diagnostic solution to test for virulent bacterial infection from Streptococcus pneumoniae and viral lung infections. The product enables healthcare providers to differentiate between bacterial and viral etiologies of lower respiratory tract infections, supporting appropriate treatment decisions.
Differentiator
Problem solved
Functional benefit
Products and services
- Avisa Diagnostic Test for Bacterial and Viral Lung Infection
Companies that use Avisa Pharma
Customer profileIdeal customer profiles1 record
Avisa Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Avisa Pharma competitors and assessment
Company assessmentBroad incumbents
- BioFire Diagnostics (bioMérieux): BioFire's FilmArray Pneumonia Panel directly competes in the bacterial/viral lower respiratory infection testing space that Avisa targets, and is the entrenched incumbent in syndromic respiratory PCR diagnostics within U.S. hospitals.
- QIAGEN: QIAGEN provides a broad molecular diagnostics portfolio including QIAstat-Dx Respiratory Panel, competing with Avisa in the bacterial vs viral respiratory pathogen testing category at hospital and reference lab customers.
- Becton, Dickinson and Company (BD): BD's BD MAX System and respiratory molecular assays serve the same bacterial/viral respiratory testing workflows that Avisa targets, positioning BD as a large strategic competitor in clinical microbiology labs.
- Abbott Diagnostics: Abbott's molecular and rapid diagnostics businesses (e.g., ID NOW, m2000) address bacterial and viral respiratory infections and represent the broad-incumbent competitor an emerging infectious-disease diagnostic must displace.
Direct peers
- Cepheid (Danaher): Cepheid's GeneXpert/Xpert systems offer rapid molecular testing for respiratory pathogens including bacterial and viral targets, directly comparable to Avisa's stated bacterial/viral lung infection testing value proposition.
- GenMark Diagnostics (Roche): GenMark's ePlex Respiratory Pathogen Panel multiplexes bacterial and viral respiratory targets and is a direct competitive reference for any syndromic respiratory diagnostic Avisa would bring to market.
- QuidelOrtho: QuidelOrtho markets Sofia and Savanna rapid diagnostic platforms targeting respiratory infections including bacterial and viral differentiation, making it a directly comparable point-of-care diagnostics peer.
Emerging players
- Accelerate Diagnostics: Accelerate Diagnostics focuses on rapid identification and antimicrobial susceptibility for serious infections, conceptually adjacent to Avisa's goal of rapidly identifying virulent bacterial pneumonia to guide therapy.
- Meso Scale Diagnostics: MSD develops multiplexed immunoassay platforms for infectious disease and biomarker testing, representing an emerging technology peer for any Avisa assay built on serology or protein-based pathogen detection.
- T2 Biosystems: T2 develops rapid molecular diagnostics for infectious disease, including sepsis and respiratory pathogens, making it an emerging peer with overlapping technology and clinical use cases to Avisa's diagnostic approach.
Market position
Customer concentration
Avisa Pharma social profiles
Digital presenceAvisa Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avisa Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Avisa Pharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avisa Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avisa Pharma
What does Avisa Pharma do?
Avisa Pharma provides a diagnostic solution to test for virulent bacterial infection from Streptococcus pneumoniae and viral lung infections. The product enables healthcare providers to differentiate between bacterial and viral etiologies of lower respiratory tract infections, supporting appropriate treatment decisions.
When was Avisa Pharma founded?
Avisa Pharma was founded in 2010. It employs 1 to 10 people.
Where is Avisa Pharma based?
Avisa Pharma is headquartered in Santa Fe, United States, in the North America region.
Who are Avisa Pharma's main competitors?
Broad incumbents on record are BioFire Diagnostics (bioMérieux), QIAGEN, Becton, Dickinson and Company (BD) and Abbott Diagnostics. Direct peers are Cepheid (Danaher), GenMark Diagnostics (Roche) and QuidelOrtho. Emerging players are Accelerate Diagnostics, Meso Scale Diagnostics and T2 Biosystems.
Does Avisa Pharma have an API?
No public API is recorded for Avisa Pharma.
What industry is Avisa Pharma in?
Avisa Pharma's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 621511 and its SIC code is 2835.